Effect of canagliflozin on endothelial function in patients with type 2 diabetes
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000024667
- Lead Sponsor
- Medical Center for Translational and Clinical Research, Hiroshima University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 6
Not provided
1. Has history of hypersensitivity to Canagliflozin 2. Has history of administration of SGLT2 inhibitor within 4 weeks before initiation of the study 3.patient with insulin dependent diabetes mellitus 4. Has history of myocardial infarction, angina, cerebral infarction, intracranial hemorrhage, subarachnoid hemorrhage, transient ischemic attacks within 3 months before initiation of the study 5. patient with ASO 6. With severe renal dysfunction (eGRF <45 mL/min or patient undergoing artificial dialysis) 7. Has history of severe ketosis, diabetic coma, or precoma within 6 months 8. Has history of cancer, severe infection 9. Pregnant, possibly pregnant, planned to become pregnant or nursing women 10. Are considered not eligible for the study by the attending doctor due to other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in FMD from baseline to 2 hours and 12 weeks
- Secondary Outcome Measures
Name Time Method